BR112015031088A2 - composições e métodos de imunização contra c. difficile - Google Patents

composições e métodos de imunização contra c. difficile

Info

Publication number
BR112015031088A2
BR112015031088A2 BR112015031088A BR112015031088A BR112015031088A2 BR 112015031088 A2 BR112015031088 A2 BR 112015031088A2 BR 112015031088 A BR112015031088 A BR 112015031088A BR 112015031088 A BR112015031088 A BR 112015031088A BR 112015031088 A2 BR112015031088 A2 BR 112015031088A2
Authority
BR
Brazil
Prior art keywords
difficile
toxin
patient
methods against
immunization compositions
Prior art date
Application number
BR112015031088A
Other languages
English (en)
Portuguese (pt)
Inventor
Foglia Ginamarie
De Bruyn Guy
Pietrobon Patricia
Gurunathan Sanjay
Original Assignee
Sanofi Pasteur Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51168412&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015031088(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Pasteur Inc filed Critical Sanofi Pasteur Inc
Publication of BR112015031088A2 publication Critical patent/BR112015031088A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112015031088A 2013-06-14 2014-06-13 composições e métodos de imunização contra c. difficile BR112015031088A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361835246P 2013-06-14 2013-06-14
PCT/US2014/042298 WO2014201346A1 (en) 2013-06-14 2014-06-13 Compositions and methods of immunizing against c. difficile

Publications (1)

Publication Number Publication Date
BR112015031088A2 true BR112015031088A2 (pt) 2017-07-25

Family

ID=51168412

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015031088A BR112015031088A2 (pt) 2013-06-14 2014-06-13 composições e métodos de imunização contra c. difficile

Country Status (12)

Country Link
US (4) US9730994B2 (https=)
EP (1) EP3007724B1 (https=)
JP (1) JP6691477B2 (https=)
KR (1) KR20160020543A (https=)
CN (1) CN105611942A (https=)
AU (1) AU2014277981B2 (https=)
BR (1) BR112015031088A2 (https=)
CA (1) CA2915279A1 (https=)
MX (1) MX2015017257A (https=)
SG (1) SG11201510166YA (https=)
TW (1) TWI648063B (https=)
WO (1) WO2014201346A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR086199A1 (es) 2011-04-22 2013-11-27 Wyeth Llc Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
JP6691477B2 (ja) 2013-06-14 2020-04-28 サノフィ パストゥール インコーポレイテッド クロストリジウム・ディフィシル（ｃ．ｄｉｆｆｉｃｉｌｅ）に対して免疫する組成物及び方法
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
KR102625114B1 (ko) * 2017-09-28 2024-01-12 화이자 인코포레이티드 클로스트리디움 디피실레에 대항한 면역 반응을 도출하기 위한 조성물 및 방법
EP4168032A2 (en) 2020-06-19 2023-04-26 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071759A (en) 1986-05-30 1991-12-10 The United States Of America As Represented By The Secretary Of The Army Hybridoma cell lines and monoclonal antibodies to clostridum difficile toxins A and B
EP2305293A3 (en) 1997-10-20 2013-11-06 Sanofi Pasteur Biologics Co. Immunization against Clostridium difficile disease
US6969520B2 (en) 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
HUE037932T2 (hu) 2007-09-14 2018-09-28 Sanofi Pasteur Biologics Llc Clostridium difficile A és B toxoidjait tartalmazó gyógyászati kompozíciók
GB0921288D0 (en) 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
AR086199A1 (es) 2011-04-22 2013-11-27 Wyeth Llc Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos
AR089797A1 (es) 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
GB201206070D0 (en) 2012-04-04 2012-05-16 Health Prot Agency Clostridium difficile antigens
EP2970400A1 (en) * 2013-03-15 2016-01-20 Sanofi Pasteur, Inc. Toxoid, compositions and related methods
KR20150133770A (ko) 2013-03-15 2015-11-30 사노피 파스퇴르 인코포레이티드 톡소이드, 조성물 및 관련 방법
JP6691477B2 (ja) 2013-06-14 2020-04-28 サノフィ パストゥール インコーポレイテッド クロストリジウム・ディフィシル（ｃ．ｄｉｆｆｉｃｉｌｅ）に対して免疫する組成物及び方法

Also Published As

Publication number Publication date
JP2016521754A (ja) 2016-07-25
SG11201510166YA (en) 2016-01-28
US20210145956A1 (en) 2021-05-20
AU2014277981A1 (en) 2016-01-07
JP6691477B2 (ja) 2020-04-28
CA2915279A1 (en) 2014-12-18
US9730994B2 (en) 2017-08-15
US20170304423A1 (en) 2017-10-26
US11419930B2 (en) 2022-08-23
KR20160020543A (ko) 2016-02-23
TW201536314A (zh) 2015-10-01
TWI648063B (zh) 2019-01-21
EP3007724B1 (en) 2023-07-05
CN105611942A (zh) 2016-05-25
AU2014277981B2 (en) 2019-06-20
US20200113991A1 (en) 2020-04-16
MX2015017257A (es) 2016-11-11
US20160120968A1 (en) 2016-05-05
EP3007724A1 (en) 2016-04-20
WO2014201346A1 (en) 2014-12-18

Similar Documents

Publication Publication Date Title
BR112015031088A2 (pt) composições e métodos de imunização contra c. difficile
BR112017013891A2 (pt) composições imunogênicas para uso em vacinas pneumocócicas
BR112017001796A2 (pt) composições de flagelina e seus usos
MX2019008564A (es) Composiciones inmunogenicas para su uso en vacunas neumococicas.
ECSP18001613A (es) Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas
BR112017012344A2 (pt) anticorpos anti-c10orf54 e usos dos mesmos
AR097178A1 (es) Diagnóstico y terapias anticáncer que comprenden células madre cancerosas
BR112018006243A2 (pt) formas de cristal de mononucleotídeo de beta-nicotinamida
BR112013018920A2 (pt) composições de nanopartículas, formulações destas e seus usos
BR112014018815A8 (pt) Composição imunogênica compreendendo conjugado proteína-polissacarídeo x de n. meningitidis
EA201691443A1 (ru) Накожное восстановление иммунобаланса
BR112017003346A2 (pt) derivados de pirazolopiridina, seus usos, e composição farmacêutica
MX2015012833A (es) Composiciones antibioticas de ceftolozano.
BR112017014343A2 (pt) composição contendo quitina e proteínas digeríveis
MX2022011167A (es) Metodos para mejorar las respuestas inmune innata y/o deteccion de patogenos de la mucosa mediante oligosacaridos de la leche humana.
BR112013018642A2 (pt) vacinas e composições contra streptococcus pneumoniae
CY1119957T1 (el) Θεραπεια νοσηματων με τη χρηση ανοχογονου φαρμακευτικου παρασκευασματος
EA201790958A1 (ru) Сублингвальный препарат рилузола
BR112017000519A2 (pt) "composição imunogênica, e, método para proteger um mamífero contra uma infecção meningocócica"
MX2016008397A (es) Composicion para usarse en el tratamiento de tos persistente.
BR112018068342A2 (pt) vacina de vírus zika vivo atenuado
BR112017015159A2 (pt) preparação e uso de produtos plaquetários
BR112018069682A2 (pt) métodos de tratamento para doenças colestáticas e fibróticas
PH12016500766A1 (en) Age-tailored nutritional compositions with a varying protein content
BR112016027383A8 (pt) derivados de naftiridinadiona, seus usos, composição farmacêutica e combinação

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]